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It was recently demonstrated that TLR4 activation via dietary lipids triggers inflammatory pathway and alters insulin
responsiveness in the fat tissue during obesity. Here, we question whether other TLR family members could participate in the TLR-
mediated inflammatory processes occurring in the obese adipose tissue. We thus studied the expression of TLR1, TLR2, TLR4, and
TLR6 in adipose tissue. These receptors are expressed in omental and subcutaneous human fat tissue, the expression being higher
in the omental tissue, independently of the metabolic status of the subject. We demonstrated a correlation of TLRs expression
within and between each depot suggesting a coregulation. Murine 3T3-L1 preadipocyte cells stimulated with Pam3CSK4 induced
the expression of some proinflammatory markers. Therefore, beside TLR4, other toll-like receptors are differentially expressed in
human fat tissue, and functional in an adipocyte cell line, suggesting that they might participate omental adipose tissue-related
inflammation that occurs in obesity.
1. Introduction
Toll-like receptors (TLRs) are transmembrane receptors
initiating a range of host defense mechanisms in response
to microbial products [1, 2]. Activation of the TLRs leads
to activation of intracellular signaling pathways which
results in the production of inflammatory cytokines, or
chemokines, inducing the development of antigen-specific
adaptive immunity. The TLR family contains 10 members
in humans (TLR1-10). These receptors recognize pathogen-
associated molecular patterns as well as host-derived ligands
released by various cell types during immune responses. This
leads to signaling events resulting in acute host responses
necessary to kill the pathogens [3]. This activation is
beneficial for the host but can become deleterious if resulting
in chronic inflammation [4].
Beside their role in innate and adaptive immune
responses, TLRs have been recently described to regulate
energy metabolism, mostly through acting on adipose tissue.
In particular, it was demonstrated that TLR4, the receptor for
recognition of gram-negative bacterial cell wall components,
was able to sense free fatty acids and to induce insulin
resistance in adipose tissue [5]. TLR2, as TLR4, has been
shown to be activated by saturated free fatty acids [6] and
is implied in bacterial lipoprotein recognition [7]. Unlike
other TLRs, which are functionally active as homodimers,
TLR2 can form heterodimers with TLR1 or TLR6 that will
recognize distinct molecular patterns of lipopeptides and can
discriminate between tri- and diacylated lipopeptides [8, 9].
Our purpose is to demonstrate that beside TLR4, TLR2 and
its partners TLR1 and TLR6 are potentially susceptible to
play also a role in adipose tissue inflammation.
2 Mediators of Inflammation
Epidemiological studies have clearly demonstrated a rela-
tionship between intraabdominal fat depots and metabolic
abnormalities related to obesity [10, 11]. In this regard,
subcutaneous and omental adipose tissues display different
metabolic features [12, 13] such as differences in lipolysis
or adipokine secretion. Physiologically, TLRs activation in
fat cells induces cytokine secretion which triggers further
inflammation. Since omental tissue is related to a higher
degree of inflammation [14], a high expression of TLRs
in this tissue may correspond to an implication of these
receptors in obesity-related inflammation.
We analyzed, TLR1, TLR2, TLR6, and TLR4 expression
in paired human adipose omental and subcutaneous samples
from subjects with different glycaemic status.
We previously demonstrated that inflammation corre-
lates with a decrease of lipogenesis [14] and that TLR4
stimulation interferes with adipocyte differentiation [15].
In order to determine whether TLR2 activation can be
also implied in proinflammatory stimulation or interact
with adipogenesis, we studied the impact of Pam3CSK4 (a
TLR1/TLR2 agonist) exposure on 3T3-L1 preadipocyte cell
line.
2. Subjects, Materials, and Methods
2.1. Reagents. Insulin, dexamethasone and, isobutyl-1-
methylxanthine were purchased from Sigma Chemical Co.
(St Louis, MO, USA). The synthetic bacterial lipoprotein
N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-
cysteinyl-[S]-seryl-[S]-lysyl-[S]-lysyl-[S]-lysyl-[S]-lysine
(Pam3CSK4) was from InvivoGen (San Diego, CA, USA).
Tetramethylbenzidine (TMB) was from BD Biosciences
(Franklin Lakes, NJ, USA).
2.2. Subjects. Forty-one Caucasian female subjects (seven
lean volunteers and thirty-four obese patients) attending
either the “De´partement de Chirurgie Ge´ne´rale et Endocrini-
enne, CHRU de Lille” or the Department of Endocrinology
of the Clı´nica Universitaria de Navarra were enrolled in
the study. The subjects were classified as normal weight or
obese according the to WHO criteria. Subjects were further
classified into 3 groups according to the recently established
diagnostic thresholds (based on an Oral Glucose Tolerance
test, OGTT) for diabetes and lesser degrees of impaired
glucose regulation (normoglycaemia: fasting plasma glucose
concentration (FPG) <100mg/dL and 2-h PG <140mg/dL
after OGTT; glucose intolerant: FPG >100mg/dL and
<125mg/dL or 2-h PG between 140 and 199mg/dL after
OGTT; type 2 diabetes mellitus: FPG ≥126mg/dL or 2-h PG
≥200mg/dL after OGTT; Table 1). The lean group included
patients undergoing surgery due to benign diseases, such
as cholecystectomy, while the 34 obese patients strictly
met the criteria for bariatric surgery. In both groups of
patients surgery was performed by the minimally invasive
laparoscopic approach. Informed consent was obtained from
all subjects and the experimental design was approved by
the Hospitals’ Ethical Committees responsible for research.
All patients underwent a preoperative evaluation including
medical history and physical examination. Biopsies were
obtained from both subcutaneous and omental adipose
tissues of lean and obese volunteers. Fat samples were
immediately frozen in liquid nitrogen and stored at −85◦C.
2.3. Cell Culture and Induction of Adipocyte Differentiation.
3T3-L1 preadipocytes were maintained and cultured in
DMEM (Gibco, Paisley, Scotland, UK) containing 10%
(vol/vol) fetal calf serum (Gibco). 3T3-L1 cells were dif-
ferentiated into adipocytes as previously described [16].
Briefly, 2-day postconfluent 3T3-L1 preadipocytes (desig-
nated day 0) were fed DMEM containing 10% FCS, 10 μg/mL
insulin, 1 μM dexamethasone, and 0.5mM 3-isobutyl-1-
methylxanthine for 2 days. Cells were then fed DMEM
supplemented with 10% FCS and 5 μg/mL insulin until day
10.
2.4. Evaluation of Gene Expression Levels by Quantitative
Real-Time RT-PCR and Quantification of Protein Secretion
by ELISA. Human samples were homogenized using an
ULTRA-TURRAX T25 basic equipment (IKA Werke GmbH,
Staufen, Germany). Total RNA was extracted from 3T3-L1
cells or from human adipose samples using RNeasy Lipid
kit (Qiagen, Courtaboeuf, France). One microgram of total
RNA was transcribed into cDNA using cDNA Archive Kit
(Applied Biosystems, Foster City, CA, USA). Each cDNA
sample was analyzed for gene expression by quantitative
real-time PCR (qPCR) using the fluorescent TaqMan 5′-
nuclease assay on an Applied Biosystems 7900HT sequence
detection system. The TaqMan real-time PCRwas performed
using 2× TaqMan Master Mix and 20× premade TaqMan
gene expression assays (Applied Biosystems). Analysis was
performed with ABI 7900HT SDS 2.2 Software. For 3T3-L1
samples, the mRNAs levels were normalized to that of acidic
ribosomal phosphoprotein (36B4), a gene whose expression
is unaffected by adipogenesis [17]. For human samples,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as reference gene, since it was previously described
to exhibit a low coefficient of variation and no significant
differences in mRNA levels between samples of the different
phenotypical groups [14]. The data are given as the ratio of
the target gene mRNA to that of GAPDH or 36B4 mRNA
level.
Concentrations of cytokines and chemokines were mea-
sured by DuoSet ELISA Development System according to
manufacturer instructions (R&D Systems, Abingdon, UK).
To further confirm the specific TLR2 activation and to
exclude potential endotoxin contamination of Pam3CSK4
agonist leading to TLR4 activation, we used a monoclonal
anti-TLR2 antibody to inhibit its biological activity (clone
T2.5 from Hycult Biotechnologies, Uden, The Netherlands,
IgG1 isotype) [18, 19]. The negative control was performed
using another IgG1 monoclonal antibody (15H6, Interchim,
Montluc¸on, France).
2.5. Statistical Analysis. Statistical analysis was performed
with the SPSS software package (14.0.2, Chicago, IL).
According to sample size, the test on ranks was performed
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Table 1: General characteristics of the study subjects.
Lean Obese Obese Obese
Normoglycemic Glucose intolerant Type 2 diabetic
(n = 7) (n = 12) (n = 11) (n = 11)
Age (yr) 42.6± 13.8 43.5± 5.0 40.7± 5.5 48.2± 7.1
BMI (kg/m2) 21.4± 2.4 44.2± 4.8 46.3± 4.8 48.8± 6.6
Fasting glucose (mmol/l) 4.38± 0.67 5.00± 0.50 5.48± 0.95 8.53± 2.13
Glucose 2h OGTT (mmol/l) n.d. 6.18± 0.72 8.51± 1.13 n.d.
Insulin (mUI/l) n.d. 11.23± 6.52 11.80± 3.82 19.92± 14.33
Mean value ± SD. Comparisons were made between the various categories of obese patients using the Kruskal-Wallis test; n.d. = not done.
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Figure 1: TLR1, TLR2, TLR4, and TLR6 mRNA expression
in adipose tissues according to localization (OM = omental,
SC = subcutaneous;) in human subjects. The data are presented
as the ratio of the levels of the target gene mRNA to that of
GAPDH mRNA. The nonparametric paired Wilcoxon test was
performed between subcutaneous and omental values for each gene
and demonstrated a significant difference between omental and
subcutaneous expression.
and two-tailed exact P-values are given. The mRNA levels
between lean and obese patients or in cell culture studies
were analyzed by U Mann-Whitney’s test. Comparisons of
mRNA levels between subcutaneous and omental adipose
tissues were performed using the paired Wilcoxon test.
Correlations between continuous variables were determined
using the nonparametric Spearman’s rank correlation. The
threshold of significance was set at P < .05.
3. Results
3.1. TLR1, TLR2, TLR4, and TLR6 Human Adipose Tissue
Expression. We first globally analyzed TLR1 and TLR2
mRNA expression in omental and subcutaneous adipose
tissue of 34 morbidly obese (BMI = 46.4 ± 5.6 kg/m2) and
7 lean subjects (BMI = 21.4 ± 2.4 kg/m2) by qPCR. We
observed an increased expression of TLRs in omental fat
compared to subcutaneous adipose tissue (1.42-, 1.35-, 1.35-,
and 1.40-fold increase for TLR1, TLR2, TLR4, and TLR6,
resp.; Figure 1). The nonparametric pairedWilcoxon test was
performed between subcutaneous and omental values for
each gene and demonstrated a significant difference. P-values
are, respectively, TLR1: 1,03 10−6; TLR2: 3.84 10−4; TLR4:
1,29 10−6; TLR6: 2.30 10−6.
We then analyzed independently each glucose tolerance
subgroup (Figure 2). It showed a consistent higher expres-
sion of TLRs in omental adipose tissue. This difference
was significant in obese normoglycemic and obese glucose
intolerant groups, never in lean group and significant for
TLR4 and TLR6 in diabetic subjects. We then performed
Spearman’s correlation analysis (nonparametric analysis
based on rank) between each TLR expression and each depot
(data not shown). For a given TLR, expressions was strongly
correlated in omental and subcutaneous adipose tissues (e.g.,
individuals with high TLR1 expression in the omental depot
also showed a high subcutaneous TLR1 level). In each given
depot, a correlation between the four TLRs expression was
also observed (e.g., individuals with a high TLR1 expression
in subcutaneous depot also display a high expression of all
other TLRs in this depot). These results suggest a common
mechanism of expression regulation.
Mann-Whitney analysis was performed to detect an
association between TLRs expression and glycaemic status.
No correlation between expression levels of TLRs and
glycaemic status was observed among obese subjects. The
only significant value obtained was between lean and obese
normoglycemic subjects in omental tissue for TLR1 and
TLR2 (P = 3.73 10−3 and 3.58 10−2, resp.)
3.2. Toll-Like Receptors Expression and TLR2 Functionality
in Murine 3T3-L1 Cell Line. To determine whether toll-
like receptors are expressed and functional in an adipocyte
cell line model, total mRNA was isolated from 3T3-L1
preadipocytes as well as fully differentiated adipocytes, and
qPCR was performed. Considering differentiated adipocytes,
the expression of TLR4 mRNA was 76 times higher than that
of TLR1, 4.6 times higher than that of TLR2 and 30 times
higher than that of TLR6. This relative expression difference
was also observed in preadipocyte but with a lower range
(Figure 3). Differentiation into adipocyte has no significant
impact on TLR2 and TLR6 expression levels while TLR1
expression is lowered (5-fold) and TLR4 is enhanced (4-
fold).
We wanted to demonstrate that, besides TLR4 as already
published [15], other TLRs can be functional in 3T3-L1 cell
line. We therefore stimulated 3T3-L1 preadipocytes and fully
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Figure 2: TLR1, TLR2, TLR4, and TLR6 mRNA expression in adipose tissues according to localization (OM = omental,
SC = subcutaneous;) and to phenotypic group (LN: lean normoglycemic; ON: obese normoglycemic; OI: obese glucose intolerant; OD:
obese diabetic) in human subjects. The nonparametric paired Wilcoxon test was performed between subcutaneous and omental values and
P-value is given in each corresponding panel (ns: P > .05).
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Figure 3: TLR1, TLR2, TLR4, and TLR6 expression in 3T3-L1 cell
line. Relative expression to 36B4 of genes coding for TLR1 and
TLR2 was measured by qPCR in preadipocytes (white) or after
ten-day differentiation of 3T3-L1 (black). Mann-Whitney analysis
was performed between preadipocytes and differentiated adipocytes
values (∗, P < .05).
differentiated adipocytes with Pam3CSK4 (a TLR1/TLR2
agonist) and measured the expression level of inflammation
markers by qPCR after 4 hours of induction. mRNA coding
for IL6, CCL2, CCL11, NOS2, CCL5, and PTGS2 was
highly induced by Pam3CSK4 stimulation in preadipocytes
as well as in fully differentiated adipocytes (Figure 4). To
further demonstrate the specificity of this stimulation and
exclude the eventuality of TLR4 stimulation via endotoxin
contamination, we used a TLR2 blocking antibody. Incu-
bation with the TLR2 antibody prevents the Pam3CSK4-
induced expression of proinflammatory markers. A mono-
clonal antibody of the same isotype was used as a control
and demonstrated no effect on the Pam3CSK4 induction.
Therefore, the stimulation of proinflammatory markers by
Pam3CSK4 can specifically be attributed to TLR2 (Figure 5).
Cell supernatants were collected and cytokine and
chemokine secretions were measured by ELISA at different
time points after Pam3CSK4 stimulation. Protein secretion
became detectable in supernatants four hours after stimu-
lation. Preadipocytes were mainly responsible for release of
IL6, whereas the CCL2, CCL5, and CCL11 concentrations
observed were in the same range for both preadipocytes
and adipocytes (Figure 5), demonstrating that adipocytes are
able to secrete proinflammatory products via TLR2/TLR1
activation in both states of differentiation.
3.3. Effect of TLR2/TLR1 Stimulation on 3T3L1 Differenti-
ation. We previously demonstrated that TLR4 stimulation
by LPS was able to impair adipocyte differentiation of 3T3-
L1 cells [15]. To demonstrate that TLR2/TLR1 is also able
to interfere with this process, we added 1 or 10 ng/mL
Pam3CSK4 to the differentiating medium throughout the
differentiation process. Microscopic observation of lipid-
laden cells stained with oil-red-o showed a slight reduction
of lipid droplets in 3T3-L1 cells cultured with Pam3CSK4 at
day four. No significant differences were observed after 10
days (data not shown). Since PPARγ is a key regulator of
adipocyte differentiation [20], we monitored its expression
level during the differentiation process. PPARγmRNA was
detected 2 days after onset of differentiation and was further
elevated at days 6 and 10. Treatment with Pam3CSK4 led to
a 50% reduction of PPARγ expression (Figure 6), demon-
strating that TLR2/TLR1 activation impairs adipogenesis.
4. Discussion
Obesity is defined as a low-grade chronic inflammatory
disease associated with a moderate increase of circulating
inflammatory factors [21]. This inflammation causes or
worsens insulin resistance in insulin-responsive tissues such
as adipose tissue, muscle, or liver. One of the causative factors
of this inflammation process is the adipose tissue itself via its
early infiltration with immune cells (mainly macrophages)
[22] and via its autocrine and paracrine secretion of pro-and
anti-inflammatory cytokines [23]. Importantly, it was shown
that macrophage infiltration is more prominent in visceral
fat than in subcutaneous fat [13, 24], thereby reinforcing
the notion that intra-abdominal fat amount and metabolic
abnormalities are correlated, as clearly shown by several
epidemiological studies [10, 11].
One member of the TLR family, namely TLR4, was
reported to participate to the development of inflammation
and insulinresistance at the adipose level [5, 25]. We thus
hypothesized that other functional members of the TLR
family of innate immune receptors might also participate in
these processes. Since, like TLR4, TLR2 was demonstrated to
sense fatty acids when dimerized either with TLR1 or TLR6
[6] we first focused our search on this receptor and on its
dimerization partners TLR1 and TLR6.
We found that TLR4, TLR1, TLR2, and TLR6 are
significantly overexpressed in omental adipose tissue. Since
a preferential macrophage infiltration into obese omental
versus subcutaneous fat was demonstrated [26], we cannot
exclude that toll-like receptors expression in adipose tissue
is mainly due to macrophages as suggested by others [27],
but has to be demonstrated since many other adipose tissue
cell types can express toll-like receptors. We observed a
strong correlation between each TLR expression within a
given adipose depot and that at the individual level, each
TLR expression is correlated positively in subcutaneous and
omental depots. This suggests a common mechanism of
regulation. In vitro, a cross-regulation between TLR4 and
TLR2 expression was demonstrated after activation of 3T3-
L1 cells with LPS, a TLR4 agonist [28]. Additionally, LPS
was also reported to slightly enhance TLR1 expression in
THP1 cells [29]. Whether LPS is the effector signal triggering
overexpression of TLRs in human omental tissue could be
hypothesized but other TLR ligands could also be involved.
Endotoxemia was shown to participate in the initiation of
obesity and insulin resistance [30], therefore serum LPS
concentration as well as free fatty acid concentration would
be interesting to be evaluated in relation to TLRs expression.
Recently, resistin was demonstrated to be able to bind to
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Figure 4: Induction of genes coding for IL6, CCL2, CCL5, CCL11, NOS2, and PTGS2 was measured by qPCR in preadipocytes (a) or
in differentiated 3T3L1 (b) after 4 hours stimulation with 1 ng/mL Pam3CSK4 in the absence (white) or presence of a blocking antibody
(25 μg/mL; grey) or an isotypic control (25 μg/mL; black). Mann-Whitney analysis was performed between values obtained in absence or
presence of antibodies (∗, P < .05).
TLR4 [31], and other endogenous ligands such as HMGB1 or
hyaluronan fragments were also reported as TLR4 or TLR2
activators [32]. Whether different TLR activators in obesity
are of endogenous or exogenous origins or even of both,
remained to be investigated and will be crucial for a better
comprehension of this chronic inflammation.
We previously demonstrated that the inflammatory state
associated with a decreased expression of lipogenic markers
wasmore pronounced in diabetic subjects [14].We could not
reveal any differential expression according the prediabetic
or diabetic status of the subjects. This might suggest that
omental overexpression of toll-like receptors could play a
role in early prediabetic phases of metabolic syndrome
acquisition but not in further complications.
Activation of TLR2 by saturated fatty acids leads to
the activation of MyD88-dependent signaling pathways
whatever heterodimer is implied [6]. We here demonstrate
that proinflammatory products can be synthesized by 3T3-
L1 cells following TLR2/TLR1 activation. We have used
the well-known 3T3T-L1 murine preadipocyte cell line as
an in vitro system for adipocyte generation to study the
inflammatory response of both preadipocytes and adipocytes
upon TLRs stimulation. The expression level of TLRs in 3T3-
L1 cell line has not to be compared to what was obtained
from human samples since adipose tissue is constituted of
numerous different cell types (e.g., adipocytes, macrophages,
and endothelial cells). Our purpose was to stress out the
potential responsiveness of the adipocyte or of its precursors
toward stimulatory compounds of the TLR2 pathway. We
had already shown that IL-6, certain chemokines (CCL2,
CCL2, and CCL11), inducible nitric oxide synthase (NOS2),
and cyclooxygenase-2 (PTGS2), all important mediators
of inflammation, can be induced via TLR4 activation in
the 3T3-L1 cell line [15]. We demonstrate here that these
molecules are also inducible specifically through TLR2/TLR1
activation. TLR4 activation induced a lower secretion of
IL6, CCL5, and CCL11 in adipocytes when compared to
preadipocytes, while CCL2 secretion was similar in both dif-
ferentiation states [15]. Following TLR2 activation, only the
secretion of IL-6 was lower in differentiated adipocytes than
in preadipocytes. Similarly, we observed different induction
factors for mRNA levels of the proinflammatory enzymes
NOS2 and PTGS2 in this study of activation via TLR2 and
in the previous study of activation via TLR4 [15]. Recently,
an exhaustive study of TLR1 to TLR9 activation of adipocyte
with corresponding ligands was reported demonstrating a
distinct response for each receptor [33]. As stated before,
the pertinence of these observations will be strengthened
when the “in vivo” genuine ligands will be described. We
have observed that TLR2 and TLR6 expression is constant
throughout differentiation of 3T3-L1 cells, whereas TLR1
and TLR4 expression is modulated in fully differentiated
adipocytes. Whether this could explain the weaker secretion
of IL-6 observed in fully differentiated adipocyte can be
hypothesized. We suggest that a fine regulation of the
synthesis of proinflammatory mediators could be achieved
in adipose tissue via differential expression and activation of
TLR family members. As for TLR4 stimulation, we were not
able to detect any TNFα transcripts in Pam3CSK4-stimulated
3T3-L1 preadipocytes. This is in agreement with previous
observation that showing TNFα release in human adipose
tissue is mainly due to nonfat cells [34].
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Figure 5: IL6, CCL2, CCL5, and CCL11 secretion was measured by ELISA in supernatants of preadipocytes ( ) or differentiated 3T3-L1
(©) at different periods of time after stimulation with 1 ng/mL Pam3CSK4. All the results are presented as one experiment representative of
at least three independent experiments.
To conclude, we demonstrate here that TLR2/TLR1
activation is able to interfere with adipocyte differentiation
in the 3T3-L1 cell line, as previously described for TLR4
[15]. This could occur either directly or via secretion
of adipoctye-derived proinflammatory and antiadipogenic
products. This observation is in agreement with our previous
study demonstrating that the expression of lipogenic factors
is reduced in omental adipose tissue in correlation with
inflammation increase [14].
Beside their defense function of alerting the immune
system of the presence of pathogenic microorganisms, TLRs
can also sense dietary lipids. Therefore, it is tempting to
speculate that detection of abnormal level or composition
of these lipids will induce a physiological response. Our
observations suggest that it might be the case and that,
in addition to TLR4, other TLR family members, that
are functional and present in adipocytes, could play this
role. Unfortunately, the physiological response results in
elicitation of a chronic omental adipose inflammation which
contributes to metabolic syndrome.
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Figure 6: PPARγ mRNA relative expression to 36B4 during 3T3-L1
differentiation (white) and during differentiation with continuous
exposure to 1 ng/mL (grey) or 10 ng/mL (black) Pam3CSK4.
Mann-Whitney analysis was performed between values obtained in
absence or presence of Pam3SCK4 (∗, P < .05).
Pam3CSK4: N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-
propyl]-[R]-cysteinyl-[S]-seryl-[S]-lysyl-[S]-
lysyl-[S]-lysyl-[S]-lysine
PTGS2: Prostaglandin-endoperoxide synthase
2 = cyclooxygenase 2 = COX2
36B4: Acidic ribosomal phosphoprotein.
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